Head-to-head evidence
IBI3032 vs orforglipron
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
IBI3032
Developed by Innovent Biologics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
orforglipron · Foundayo
Marketed by Eli Lilly
NCT05803421 · Phase 3 · completed
The study is randomized and active-controlled with a large sample of 2,749 participants, but it is open-label rather than blinded. Its primary endpoint is a hard clinical cardiovascular outcome; however, the comparison cannot be judged because no results are currently available.
Next expected readout: February 2027 · NCT06672549 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: IBI3032's landscape · orforglipron's landscape